Advance Search

Comparative study of intralesional steroid versus intralesional vitamin D3 in patients with alopecia areata

Sarmad Abdulrahman Sulaiman
University of Kurdistan, Erbil, Iraq.
Rebwar Abdulla Ahmad
Ministry of Health, Erbil, Kurdistan Region, Iraq.
Askol Sadradeen Nuradeen
Ministry of Health, Erbil, Kurdistan Region, Iraq.
Baref Zahir Rashid
Kurdistan Higher Council of Medical Specialities (KHCMS), Ministry of Health, Erbil, Iraq.
Keywords:
Copyright and Licensing:

Copyright (c) 2025 Sarmad Abdulrahman Sulaiman, Rebwar Abdulla Ahmad, Askol Sadradeen Nuradeen, Baref Zahir Rashid (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Share:
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Background and objective: Alopecia areata is a non-scarring type of patchy hair loss accompanied by profound psychological distress. This study aims to assess the effectiveness of intralesional triamcinolone acetonide against intralesional vitamin D3 injection in treating alopecia areata.

Methods: This interventional therapeutic study was conducted on 40 adult patients who were divided into two groups. For a maximum of three sessions, 20 patients in Group I received intralesional injections of vitamin D3 (cholecalciferol aqueous preparation 100 000 IU/2 ml) every three weeks. Twenty patients in Group II underwent three sessions of intralesional injections of triamcinolone acetonide every three weeks. Clinical assessments were conducted both at baseline and following each session.

Results: The largest proportion of the sample (42.5%) were aged 20-29 years, more than two-thirds of the patients (67.5%) were males, about 2.5% of the patients had thyroid disease and 2.5% had atopy. In both groups there was significant increase in McDonald’s score, (P <0.001). After receiving three sessions, more than half (55%) of the steroid group had terminal regrowth in all areas, compared with 25% in the Vitamin D3 group. The difference was close to the level of significance (P = 0.063). No significant association was detected between the terminal regrowth on the third session with the following variables: number of patches (P = 0.783), size of the patch (P = 0.152), area (P = 0.319), in both groups

Conclusion: For patchy alopecia areata, both intralesional steroid and intralesional vitamin D3 are easy, safe, and affordable treatment options.

PDF
PDF

Metrics

Metrics Loading ...

References

  1. Lintzeri DA, Constantinou A, Hillmann K, Ghoreschi K, Vogt A, Blume‐ Peytavi U. Alopecia areata – Current understanding and management. JDDG J Dtsch Dermatol Ges. 2022; 20(1):59–90. https://doi.org/10.1111/ddg.14689
  2. Darwin E, Hirt PA, Fertig R, Doliner B, Delcanto G, Jimenez JJ. Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options. Int J Trichology. 2018; 10(2):51-60. doi: 10.4103/ijt.ijt_99_17. PMID: 29769777; PMCID: PMC5939003.
  3. Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015; 8:397-403. doi: 10.2147/CCID.S53985. PMID: 26244028; PMCID: PMC4521674.
  4. Olayinka J (Jadé) T, Richmond JM. Immunopathogenesis of alopecia areata. Curr Res Immunol. 2021; 2:7–11. https://doi.org/10.1016/j.crimmu 2021.02.001
  5. Zhou C, Li X, Wang C, Zhang J. Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management. Clin Rev Allergy Immunol. 2021; 61(3):403-23. doi: 10.1007/s12016-021-08883-0
  6. Sibbald C. Alopecia Areata: An Updated Review for 2023. J Cutan Med Surg. 2023; 27(3):241-259. doi: 10.1177/12034754231168839. PMID: 37340563; PMCID: PMC10291119.
  7. Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al, Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis, J Am Acaddermatol. 2018; 78(1):1-12, ISSN 0190-9622 DOI: 10.1016/j.jaad.2017.04.1141
  8. Mostaghimi A, Gao W, Ray M, Bartolome L, Wang T, Carley C, et al. Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population. JAMA Dermatol. 2023; 159(4):411-8. doi: 10.1001/jamadermatol.2023.0002. PMID: 36857069; PMCID: PMC9979012.
  9. Ragaie MH, Mohammed SE, Shehata SS. Intralesional vitamin D3 versus intralesional triamcinolone acetonide in patchy alopecia areata: a comparative clinical and dermoscopic study. J Cosmet Laser Ther. 2024; 14:1-5. doi: 10.1080/14764172.2024.2389275. Epub 2024 Aug 14.
  10. Coppola MM, Salzillo R, Segreto F, Persichetti P. Triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives. Clin Cosmet Investig Dermatol. 2018; 11:387-396. doi: 10.2147/CCID.S133672. PMID: 30087573; PMCID: PMC6063260.
  11. Abdel Meguid AM, Ghazally A, Ahmed A M, Bakr RM. Fractional carbon dioxide laser alone and as an assisted drug delivery for treatment of alopecia areata: a clinical, dermoscopic and immunohistochemical study. Arch Dermatol Res. 2023; 315:1675–88. https://doi.org/10.1007/s00403-023-02565-x
  12. Pineda JC, Alvis-Zakzuk NR, Moyano-Támara L, Fierro-Lozada J, Cera-Coll C, Celorio-Murillo W, et al. Clinical and sociodemographic characteristics of alopecia areata in five Colombian cities: an analysis by RENAAC Actas Dermosifiliogr. 2024; 115:T845-T51. https://doi.org/10.1016/j.ad.2024.02.018
  13. Uzuncakmak TK, Engin B, Serdaroglu S, Tuzun Y. Demographic and Clinical Features of 1,641 Patients with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis: A Single-Center Retrospective Study. Skin Appendage Disord. 2021; 7(1):8–12. DOI: 10.1159/000510880
  14. Al-Mosawi RH, Alebadi NAM. Usage of corticosteroids as therapeutic agents in diseases. Med J Babylon. 2023; 20:447-50. DOI:10.4103/MJBL.MJBL_391_23
  15. Kim DH, Lee JW, Kim IS, Choi SY, Lim YY, Kim HM, et al. Successful treatment of alopecia areata with topical calcipotriol. Ann Dermatol. 2012; 24:341–4. DOI: 10.5021/ad.2012.24.3.341
  16. Tsai TY, Huang YC. Vitamin D deficiency in patients with alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2018; 78:207–9. doi: 10.1016/j.jaad.2017.07.051
  17. Narang T, Daroach M, Kumaran MS., Efficacy and safety of topical calcipotriol in management of alopecia areata: a pilot study. Dermatol Ther. 2017; 30. doi: 10.1111/dth.12464. Epub 2017 Jan 30.
  18. Rashad AF, Elgamal E, Fouda I. Intralesional vitamin D3 in treatment of alopecia areata: A randomized controlled clinical trial. J Cosmet Dermatol. 2022; 21(10):4617-22. doi: 10.1111/jocd.14844. Epub 2022 Feb 18.
How to Cite
Abdulrahman Sulaiman, S. ., Abdulla Ahmad, R. ., Sadradeen Nuradeen, A. ., & Zahir Rashid , B. . (2025). Comparative study of intralesional steroid versus intralesional vitamin D3 in patients with alopecia areata. Zanco Journal of Medical Sciences (Zanco J Med Sci), 29(2), 372–382. https://doi.org/10.15218/zjms.2025.039

Send mail to Author

Send Cancel